Abstract
Due to the SARS-CoV-2 pandemic, there has been an increase in the search for affordable healthcare devices for mass testing and rapid diagnosis. In this context, this work described a new methodology for SARS-CoV-2 detection based on an impedimetric immunosensor developed using the advantageous immobilization of antibodies in the reduced graphene oxide (rGO). The rGO was obtained by chemical synthesis from the commercial graphene oxide (GO), and the materials were morphologically, electrochemically and visually characterized. The cyclic voltammetry (CV) and electrochemical impedance spectroscopy (EIS) techniques were used to evaluate the fabrication steps of the immunosensor. The electrochemical immunoassay was considered for SARS-CoV-2 spike protein RBD detection using a impedimetric immunosensor and redox couple ([(Fe(CN)6)]3−/4−) as a probe. The immunosensor was effectively developed and applied in the detection of SARS-CoV-2 spike protein RBD in saliva samples.
Highlights
The development of rapid tests, with significant reliability, easy applicability and low cost is essential for the context of the SARS-CoV-2 pandemic [1,2]
Developing novel electrochemical biosensors based on the detection of antigenantibody interactions or membrane proteins of SARS-CoV-2 appears as an adequate and accessible alternative of test devices to those based on reverse transcription-polymerase chain reaction (RT-PCR) to supply the world’s current demand [3,4,5,6]
Different colors can be observed for the graphene oxide (GO) and reduced graphene oxide (rGO) suspensions
Summary
The development of rapid tests, with significant reliability, easy applicability and low cost is essential for the context of the SARS-CoV-2 pandemic [1,2]. In Brazil, the development of these devices based on the national sample of patients appears as an essential and necessary opportunity for the development of national technology with low cost and accessibility, in order to minimize the bringing down effect on the health system. Developing novel electrochemical biosensors based on the detection of antigenantibody interactions or membrane proteins of SARS-CoV-2 appears as an adequate and accessible alternative of test devices to those based on reverse transcription-polymerase chain reaction (RT-PCR) to supply the world’s current demand [3,4,5,6]. The super sandwichtype electrochemical sensor presented an LOD of the clinical specimen of 200 copies/mL
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
